Jason R Bock

US Patent:

8323634, Dec 4, 2012

Filed:

Jan 15, 2010

Appl. No.:

12/688655

Inventors:

Jason Benjamin Bock - North Potomac MD, US
Xia Luo - Rockville MD, US

Assignee:

Teva Pharmaceutical Industries Ltd.

International Classification:

A61K 45/00
C07K 14/535
C12P 21/02

US Classification:

424 851, 4241921, 435 695, 435 697, 530351, 530413

Abstract:

Described herein are compositions and methods for treating, preventing and ameliorating diseases and conditions characterized by a lower than normal white blood cell count, such as leukopenia and neutropenia. The compositions and methods include recombinant human albumin-human granulocyte colony stimulating factor. Pharmaceutical formulations including the recombinant fusion protein, and methods of making such formulations are also described.

US Patent:

20070048282, Mar 1, 2007

Filed:

Aug 8, 2006

Appl. No.:

11/500314

Inventors:

Craig Rosen - Laytonsville MD, US
William Haseltine - Washington DC, US
Paul Moore - North Bethesda MD, US
Jason Bock - North Potomac MD, US
Adam Bell - Germantown MD, US
Yanggu Shi - Gaithersburg MD, US
David LaFleur - Washington DC, US

Assignee:

Human Genome Sciences, Inc. - Rockville MD

International Classification:

A61K 38/21
A61K 38/38
C12P 21/04
C12N 15/00

US Classification:

424085700, 514012000, 530350000, 530351000, 530363000, 435069510, 435069700, 435320100, 435325000

Abstract:

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

US Patent:

20080004206, Jan 3, 2008

Filed:

Jul 31, 2006

Appl. No.:

11/495624

Inventors:

Craig Rosen - Laytonsville MD, US
Adam Bell - Germantown MD, US
Paul Moore - North Bethesda MD, US
Yanggu Shi - Gaithersburg MD, US
David LaFleur - Washington DC, US
Jason Bock - North Potomac MD, US
Michael Laird - San Ramon CA, US
William Haseltine - Washington DC, US
Douglas Woods - Gaithersburg MD, US
Mani Subramanian - Ellicott City MD, US

International Classification:

A61K 38/38
C07H 21/04
C07K 14/76
C12N 15/00
C12N 5/00

US Classification:

514002000, 435252100, 435255100, 435320100, 435325000, 530362000, 536023100

Abstract:

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

US Patent:

20080194481, Aug 14, 2008

Filed:

Oct 31, 2007

Appl. No.:

11/932823

Inventors:

Craig A. Rosen - Laytonsville MD, US
Adam Bell - Germantown MD, US
Paul A. Moore - North Bethesda MD, US
Yanggu Shi - Gaithersburg MD, US
David LaFleur - Washington DC, US
Jason B. Bock - North Potomac MD, US
Michael W. Laird - San Ramon CA, US
William A. Haseltine - Washington DC, US
Douglas B. Woods - Gaithersburg MD, US
Mani Subramanian - Ellicott City MD, US

International Classification:

A61K 38/00
C07K 14/00
C12N 15/11
C12N 15/00
C12N 5/06
A61P 9/00
A61P 1/00
A61P 25/00
C12N 1/00
C12N 1/20
C12P 21/04

US Classification:

514 12, 530362, 536 234, 4353201, 435325, 4352542, 4352523, 435 697

Abstract:

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

US Patent:

20100227818, Sep 9, 2010

Filed:

Jan 15, 2010

Appl. No.:

12/688754

Inventors:

Jason Benjamin Bock - North Potomac MD, US
Adam Carr Bell - Germantown MD, US
Jeffrey Herpst - Ellicott City MD, US

International Classification:

A61K 38/18
A61P 37/04

US Classification:

514 12

Abstract:

Disclosed are compositions and methods for treating, preventing and ameliorating conditions and diseases characterized by a lowered white blood cell count. The methods and compositions described herein include a fusion polypeptide formed from human serum albumin protein (“HSA”) and human granulocyte-colony stimulating factor (“G-CSF”).

US Patent:

20110002888, Jan 6, 2011

Filed:

Jun 3, 2010

Appl. No.:

12/793658

Inventors:

Craig A. Rosen - Laytonsville MD, US
Adam Bell - Germantown MD, US
Paul A. Moore - North Bethesda MD, US
Yanggu Shi - Gaithersburg MD, US
David Lafleur - Washington DC, US
Jason B. Bock - North Potomac MD, US
Michael W. Laird - San Ramon CA, US
William A. Haseltine - Washington DC, US
Douglas B. Woods - Gaithersburg MD, US
Mani Subramanian - Ellicott City MD, US

International Classification:

A61K 38/21
C07K 14/76
A61K 38/38
C07H 21/00
C12N 15/63
C12N 5/10
A61K 38/46
A61K 38/18
A61K 38/22
A61K 39/395
A61K 38/43
C12N 9/96
A61K 39/12
A61K 38/30
A61P 35/00
A61P 3/04
A61P 3/10
A61P 3/00
A61P 37/02
A61P 9/08
A61P 9/00
A61P 9/04
A61P 1/16
A61P 25/30
A61P 31/12
A61P 9/12

US Classification:

424 857, 530362, 514 152, 536 234, 4353201, 435325, 424 946, 514 76, 514 97, 4241341, 424 941, 435188, 536 232, 514 23, 4241851, 514 86, 514 52

Abstract:

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

US Patent:

20160015789, Jan 21, 2016

Filed:

Jul 16, 2015

Appl. No.:

14/801639

Inventors:

Jason BOCK - North Potomac MD, US
Yen-Huei LIN - Rockville MD, US
Ping FENG - Germantown MD, US

Assignee:

TEVA PHARMACEUTICAL INDUSTRIES, LTD. - Petach-Tikva

International Classification:

A61K 38/27
A61K 47/26
C07K 14/61
A61K 47/34
A61K 38/38
C07K 14/765
A61K 47/22
A61K 47/02

Abstract:

A stable liquid pharmaceutical composition comprising an albumin-human growth hormone (hGH) fusion protein whose amino acid sequence is set forth as SEQ ID NO: 1 and a buffer, wherein the stable liquid pharmaceutical composition has a pH range of 5.5-6.5.

US Patent:

20140199283, Jul 17, 2014

Filed:

Jan 14, 2014

Appl. No.:

14/155021

Inventors:

Qinghai Zhao - North Potomac MD, US
Xia Luo - Rockville MD, US
Jason Bock - North Potomac MD, US

Assignee:

TEVA PHARMACEUTICAL INDUSTRIES, LTD. - Petach-Tikva

International Classification:

A61K 47/48
B65B 3/04
A61J 1/00

US Classification:

424 943, 206438, 53467

Abstract:

The present invention provides an aqueous pharmaceutical composition comprising the fusion protein whose amino acid sequence is set forth as SEQ ID No:1 and an aqueous solution comprising 40 to 60 mM sodium phosphate. The present invention further provides a lyophilized pharmaceutical composition, an reconstituted solution, a sealed package comprising the lyophilized pharmaceutical composition, and a vial comprising the lyophilized pharmaceutical or the reconstituted solution. The present invention also provides a method of producing the lyophilized pharmaceutical composition and the sealed package. The present invention also provides a method of treating a human having cocaine seeking behavior, and methods of using the aqueous pharmaceutical composition and lyophilized pharmaceutical composition.